Topiramate: A new approach to prevent migraine and epilepsy
Topiramate is one of the most versatile antiepileptic drugs (AEDs). Antiepileptic drugs are considered as the first line for monotherapy in treating migraine patients and also those with comorbid migraine and epilepsy.
Topiramate was initially developed for the treatment of epilepsy and received its first US Food and Drug Administration (FDA) approval for that purpose. Subsequently, it was shown to be effective for the prevention of migraine headaches and was FDA approved for it as well.
Topiramate is a broad-spectrum AED with a mechanism of action and is most likely to benefit patients with either episodic or chronic migraine along with epilepsy, both generalized and focal. The aim of this article is to review and provide information about relevant mechanisms of action along with much useful supportive evidence published to date on topiramate (TPM) use in both migraine headache and epilepsy patients.
This has become an intense area of interest for many researchers, but to date there has been very little publications on these both disorders with the use of TPM in patients. TPM has, in fact, been adopted as first line therapy in this patient population. It warrants future studies in order to investigate effectiveness of this treatment to determine the most effective use of this medication and improving this worst condition in patients with migraine headaches and epilepsy.